Effectiveness of UNAIDS targets and HIV vaccination across 127 countries

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 15, 2017, Pages 4017-4022

  Medlock, Jan ^a   Pandey, Abhishek ^b   Parpia, Alyssa S ^b   Tang, Amber ^b   Skrip, Laura A ^b   Galvani, Alison P ^b  

^a OREGON STATE UNIVERSITY   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

Effectiveness; HIV; Mathematical model; Vaccination

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACQUIRED IMMUNE DEFICIENCY SYNDROME NURSING; ANTIRETROVIRAL THERAPY; ARTICLE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MULTICENTER STUDY; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; SIMULATION; UNITED NATIONS; VACCINATION; VIRUS INHIBITION; VIRUS TRANSMISSION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; STATISTICS AND NUMERICAL DATA; UTILIZATION; VACCINATION COVERAGE;

AIDS VACCINES; HIV INFECTIONS; HUMANS; UNITED NATIONS; VACCINATION COVERAGE;

EID: 85031279382     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1620788114     Document Type: Article

References (37)

1. Fauci AS, Folkers GK (2009) Investing to meet the scientific challenges of HIV/AIDS. Health Aff (Millwood) 28(6):1629–1641.
2. Folkers GK, Fauci AS (2010) Controlling and ultimately ending the HIV/AIDS pandemic: A feasible goal. JAMA 304(3):350–351.
3. Fauci AS, Marston HD (2015) Focusing to achieve a world without AIDS. JAMA 313(4): 357–358.
4. UNAIDS (2014) 90–90–90: An ambitious treatment target to help end the AIDS epidemic. Available at www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf. Accessed August 22, 2016.
5. UNAIDS (2014) Fast-track: Ending the AIDS epidemic by 2030. Available at www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf. Accessed August 16, 2016.
6. Levi J, et al. (2016) Can the UNAIDS 90–90–90 target be achieved? A systematic analysis of national HIV treatment cascades. BMJ Global Health 1(2):e000010.
7. Karim SA (2016) Is the UNAIDS target sufficient for HIV control in Botswana? Lancet HIV 3(5):e195–e196.
8. UNAIDS (2014) The gap report. Available at www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf. Accessed August 22, 2016.
9. Rerks-Ngarm S, et al.; MOPH-TAVEG Investigators (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361(23):2209–2220.
10. Gray GE, Laher F, Lazarus E, Ensoli B, Corey L (2016) Approaches to preventative and therapeutic HIV vaccines. Curr Opin Virol 17:104–109.
11. National Institute of Allergy and Infectious Diseases (2016) First new HIV vaccine efficacy study in seven years has begun. Available at https://www.niaid.nih.gov/newsevents/first-new-hiv-vaccine-efficacy-study-seven-years-has-begun. Accessed January 19, 2017.
12. AVAC (2016) HVTN 702. Available at www.avac.org/trial/hvtn-702. Accessed January 31, 2017.
13. Baden LR, et al.; B003-IPCAVD004-HVTN091 Study Group (2016) Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: A randomized trial. Ann Intern Med 164(5):313–322.
14. Borducchi EN, et al. (2016) Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature 540(7632):284–287.
15. AVAC (2016) HIV vaccine research: An update. Available at www.avac.org/sites/default/files/resource-files/HIV_VAX_research_update_sep_2016_web.pdf. Accessed January 30, 2017.
16. Fauci AS (2016) An HIV vaccine: Mapping uncharted territory. JAMA 316(2):143–144.
17. Evans TG, Schrager L, Thole J (2016) Status of vaccine research and development of vaccines for tuberculosis. Vaccine 34(26):2911–2914.
18. RTS,S Clinical Trials Partnership (2015) Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. Lancet 386(9988): 31–45.
19. Hotez PJ, et al. (2013) The human hookworm vaccine. Vaccine 31(Suppl 2):B227–B232.
20. Hotez P (2011) Enlarging the “Audacious Goal”: Elimination of the world’s high prevalence neglected tropical diseases. Vaccine 29(Suppl 4):D104–D110.
21. Stover J, et al.; Fast Track modeling working group (2016) What is required to end the AIDS epidemic as a public health threat by 2030? The cost and impact of the Fast-Track approach. PLoS One 11(5):e0154893.
22. Walensky RP, et al. (2016) The anticipated clinical and economic effects of 90–90–90 in South Africa. Ann Intern Med 165(5):325–333.
23. Maddali MV, Gupta A, Shah M (2016) Epidemiological impact of achieving UNAIDS 90-90-90 targets for HIV care in India: A modelling study. BMJ Open 6(7):e011914.
24. Harmon TM, et al. (2016) Exploring the potential health impact and cost-effectiveness of AIDS vaccine within a comprehensive HIV/AIDS response in low- and middle-income countries. PLoS One 11(1):e0146387.
25. Moodley N, Gray G, Bertram M (2016) Projected economic evaluation of the national implementation of a hypothetical HIV vaccination program among adolescents in South Africa, 2012. BMC Public Health 16:330.
26. Skarbinski J, et al. (2015) Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med 175(4):588–596.
27. Cohen J (2016) South Africa’s bid to end AIDS. Science 353(6294):18–21.
28. Associated Press (2016) Indonesia’s president is defending his country’s use of the death penalty for drug offenses, arguing that drug abuse constitutes an emergency. Available at bigstory.ap.org/article/18994955e4074a3d949b7c4bf45392c7/indonesian-president-defends-death-penalty-drug-crimes. Accessed August 20, 2016.
29. Mahajan AP, et al. (2008) Stigma in the HIV/AIDS epidemic: A review of the literature and recommendations for the way forward. AIDS 22(Suppl 2):S67–S79.
30. Wilson DP, Stoové MA, Hellard M (2015) A reality check for aspirational targets to end HIV. Lancet HIV 2(1):e11.
31. Bailey RC, et al. (2007) Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. Lancet 369(9562):643–656.
32. Walensky RP, et al. (2012) The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis 54(10):1504–1513.
33. Byrareddy SN, et al. (2014) Targeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection. Nat Med 20(12):1397–1400.
34. Senthilingam M (July 20, 2015) World Health Organization to recommend early treatment for everyone with HIV. Nature, 10.1038/nature.2015.18017.
35. Eholié SP, et al. (2016) Antiretroviral treatment regardless of CD4 count: The universal answer to a contextual question. AIDS Res Ther 13:27.
36. Korenromp EL, et al. (2015) Impact and cost of the HIV/AIDS national strategic plan for Mozambique, 2015–2019: Projections with the Spectrum/Goals model. PLoS One 10(11):e0142908.
37. Stover J, et al.; New Prevention Technology Study Group (2014) How can we get close to zero? The potential contribution of biomedical prevention and the investment framework towards an effective response to HIV. PLoS One 9(11):e111956.